| 000 | 01811 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250517045043.0 | ||
| 264 | 0 | _c20160407 | |
| 008 | 201604s 0 0 eng d | ||
| 022 | _a1177-8881 | ||
| 024 | 7 |
_a10.2147/DDDT.S86725 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChoi, YoonJung | |
| 245 | 0 | 0 |
_aComparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers. _h[electronic resource] |
| 260 |
_bDrug design, development and therapy _c2015 |
||
| 300 |
_a4127-35 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents, Non-Steroidal _xadministration & dosage |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 | _aChemistry, Pharmaceutical |
| 650 | 0 | 4 | _aCross-Over Studies |
| 650 | 0 | 4 | _aDrug Combinations |
| 650 | 0 | 4 |
_aEsomeprazole _xadministration & dosage |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHealthy Volunteers |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMetabolic Clearance Rate |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 |
_aNaproxen _xadministration & dosage |
| 650 | 0 | 4 |
_aProton Pump Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aRepublic of Korea |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aHan, HyeKyung | |
| 700 | 1 | _aShin, Dongseong | |
| 700 | 1 | _aLim, Kyoung Soo | |
| 700 | 1 | _aYu, Kyung-Sang | |
| 773 | 0 |
_tDrug design, development and therapy _gvol. 9 _gp. 4127-35 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2147/DDDT.S86725 _zAvailable from publisher's website |
| 999 |
_c25153964 _d25153964 |
||